The purpose of this study is to assess the body composition and growth measurements at time of NICU discharge of preterm infants who experienced acute kidney injury during their hospitalization, and to compare this with matched controls who did not experience acute kidney injury.THIS STUDY IS ENROLLING BY INVITATION ONLY - All patients admitted to the Riley Hospital Maternity Tower NICU from the date of IRB approval will be screened for eligibility. Outborn infants will be included if admitted within the first week of life. On a weekly basis, research staff will review the census at Riley Hospital Maternity Tower NICU to identify patients nearing discharge (~3-4 weeks prior to discharge). Cases and controls will be determined based on protocol criteria. If the infant is determined to meet eligibility criteria for either group, the parent(s)/caregiver(s) will be approached for consent by research staff or one of the investigators approximately 2 weeks prior to anticipated discharge. The study will be discussed, and participation will be offered. 

The purpose of this study is to investigate the efficacy, safety, and tolerability of baxdrostat in combination with dapagliflozin, compared with placebo and dapagliflozin, in reducing the risk of the composite of > 50% decline in eGFR, kidney failure, or CV death, in individuals with CKD and HTN.THIS STUDY IS ENROLLING BY INVITATION ONLY

This study will compare fluid status evaluation by different modalities which include patient score (using a scale called modified medical research council dyspnea scale), physical examination by kidney doctor and Lung Ultrasound in order to learn the best way to judge how much fluid patients on home dialysis (including peritoneal dialysis and home hemodialysis) have.THIS STUDY IS ENROLLING BY INVITATION ONLY - Current patients to the Davita home dialysis clinic of Indianapolis, that meet the inclusion criteria and agree to participate will be consented by the research team.

A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this study is to help us better understand addiction and the risk for developing alcoholism and to help us understand how the brain makes choices about drinking alcohol. THIS STUDY IS ENROLLING BY INVITATION ONLY 

This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.